PET/CT imaging with novel radiotracers such as CCR2-targeting [64Cu]-DOTA-ECL1i offers a potentially novel and non-invasive method for visualizing and quantifying inflammation within the AAA wall tissue. The gene discussed is CCR2; the disease is triple-A syndrome.